With 0.88 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.66 million shares. The 52-week range on MD shows that it touched its highest point at $17.67 and its lowest point at $6.62 during that stretch. It currently has a 1-year price target of $18.36. Beta for the stock currently stands at 1.49.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of MD was down-trending over the past week, with a drop of -7.46%, but this was up by 0.69% over a month. Three-month performance dropped to -1.63% while six-month performance rose 31.67%. The stock gained 60.33% in the past year, while it has gained 10.59% so far this year. A look at the trailing 12-month EPS for MD yields -1.20 with Next year EPS estimates of 1.62. For the next quarter, that number is 0.24. This implies an EPS growth rate of 2.07% for this year and 5.41% for next year. EPS is expected to grow by 2.86% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 41.89%.
Float and Shares Shorts:
At present, 85.87 million MD shares are outstanding with a float of 84.65 million shares on hand for trading.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for MD since 3 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $1.39979 being high and $1.26981 being low. For MD, this leads to a yearly average estimate of $1.3498. Based on analyst estimates, the high estimate for the next quarter is $0.45 and the low estimate is $0.39. The average estimate for the next quarter is thus $0.42.
Summary of Insider Activity:
Insiders traded MD stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.
